NCT06959550View on ClinicalTrials.gov

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2030

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Ivonescimab

Given by IV

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Summit Therapeutics

All Listed Sponsors

collaborator

Akesobio Australia Pty Ltd

INDUSTRY

collaborator

Summit Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06959550 - Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter